Abortion pill restriction may drive more patients to off-label drug

The Wednesday (16 August) announcement that a US appeals court upheld restrictions on abortion pill mifepristone is likely to increase sales of its counterpart, misoprostol.

The US appeals court of the Fifth Circuit, which hears cases from district courts in Mississippi, Louisiana and Texas, has ruled that the drug can remain on the market, but that REMS changes made in 2016, which increased availability and almost doubled the time after pregnancy that the drug, could be taken must be reversed.